13808-66-7

Basic information

• Product Name: 4-BroMo-3-Methyl-5-phenyl-1H-pyrazole
• Synonyms: 4-BroMo-3-Methyl-5-phenyl-1H-pyrazole;4-Bromo-3-methyl-5-phenylpyrazole
• CAS NO: 13808-66-7
• Molecular Formula: C₁₀H₉BrN₂
• Molecular Weight: 237.09586
• Mol File: 13808-66-7.mol
• Article Data: 5

Chemical Properties

• Melting Point: 87-92°C
• Appearance: /
• CAS DataBase Reference: 4-BroMo-3-Methyl-5-phenyl-1H-pyrazole(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BroMo-3-Methyl-5-phenyl-1H-pyrazole(13808-66-7)
• EPA Substance Registry System: 4-BroMo-3-Methyl-5-phenyl-1H-pyrazole(13808-66-7)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36/37/38
• Safety Statements: 26-36/37/39
• WGK Germany: 3
• Hazardous Substances Data: 13808-66-7(Hazardous Substances Data)

Usage

General Description

4-Bromo-3-Methyl-5-Phenyl-1H-pyrazole is a chemical compound with the molecular formula C10H9BrN2. It is a pyrazole derivative that contains a bromo and a methyl group on the third and fifth carbon atoms, respectively, and a phenyl group attached to the first carbon atom. This chemical is primarily used in medicinal chemistry and pharmaceutical research as a building block for the synthesis of various pharmaceutical compounds. It has also been studied for its potential biological activities, including its anti-inflammatory and analgesic properties, making it a target for drug development. Additionally, 4-Bromo-3-Methyl-5-Phenyl-1H-pyrazole has been investigated for its potential use as a ligand in coordination chemistry and in the development of new materials.

Upstream product

• 56426-41-6 3-methyl-5-phenylpyrazole 
• 3347-62-4 5-methyl-3-phenyl-1H-pyrazole 
• 939-03-7 3-methyl-5-phenyl-4,5-dihydro-1H-pyrazole 
• 67-66-3 chloroform 
• 7726-95-6 bromine 
• 93-91-4 1-phenylbutan-1,3-dione 
• 84691-22-5 4,4-Dibromo-3-methyl-5-phenyl-4H-pyrazole 
• 100-52-7 benzaldehyde 
• 67-64-1 acetone 

Downstream Products

• 1231302-31-0 2-(((1s,4s)-4-((3-methyl-5-phenyl-4-m-tolyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid 
• 1231302-54-7 2-(((1s,4s)-4-((3-(3-methoxyphenyl)-5-methyl-4-phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid 
• 1231302-53-6 2-(((1s,4s)-4-((5-(3-methoxyphenyl)-3-methyl-4-phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetic acid 
• 1231307-99-5 tert-butyl 2-(((1s,4s)-4-((4-bromo-3-methyl-5-phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate 
• 1231308-18-1 tert-butyl 2-(((1s,4s)-4-((4-bromo-5-methyl-3-phenyl-1H-pyrazol-1-yl)methyl)cyclohexyl)methoxy)acetate 
• 56426-41-6 3-methyl-5-phenylpyrazole 
• 3347-62-4 5-methyl-3-phenyl-1H-pyrazole 

Relevant articles and documents

An Efficient Synthesis of Substituted Pyrazoles from One-Pot Reaction of Ketones, Aldehydes, and Hydrazine Monohydrochloride

An efficient, one-pot and metal-free process for the preparation of 3,5-disubstituted and 3,4,5-trisubstituted pyrazoles on multi-gram scale was developed. One-pot condensation of ketones, aldehydes and hydrazine monohydrochloride readily formed pyrazoline intermediates under mild conditions. Oxidation of pyrazolines, in situ, employing bromine afforded a wide variety of pyrazoles. The methodology offers a fast, and often chromatography-free protocol for the synthesis of 3,4,5-substituted pyrazoles in good to excellent yields. Alternatively, a more benign oxidation protocol affords 3,5-disubstituted or 3,4,5-trisubstituted pyrazoles by simply heating pyrazolines in DMSO under oxygen.

PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN(PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO

Pyrazole derivatives of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).

Synthesis of 4-Bromo-1-nitropyrazoles and 1-Nitrobenzotriazoles (N-Nitroazoles)

-